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Abstract
Background: People with schizophrenia–spectrum disorders (SSD) often have high levels of obesity and poor
cardiometabolic health. Certain types of antipsychotics have been shown to contribute towards weight gain
and there is some equivocal evidence that obesity is related to poor health-related quality of life (HRQoL) in
people with SSD. It is also still uncertain if antipsychotic polypharmacy/higher doses of antipsychotics are
linked with HRQoL and/or increased risk of obesity/Cardiovascular Disease (CVD). Therefore, this study aimed
to examine potential relationships between prescribed antipsychotic medication regimens, cardiometabolic
health risks and HRQoL in community-based Chinese people with SSD.
Method: This cross-sectional study reports the results of baseline measurements of a random sample of
patients in an ongoing controlled trial of physical health intervention for people with severe mental illness.
Data from these randomly-selected participants (n = 82) were analysed to calculate 10-year CVD relative-risk
(using QRISK®2 score), estimate the prevalence of metabolic syndrome and contextualize patients’ prescribed
antipsychotics (types, combinations and Daily Defined Dose equivalent). Patients self-reported their HRQoL
(SF12v2) and their obesity condition was assessed by waist-circumference and Body Mass Index (BMI).
Results: Two-thirds of patients had a BMI ≥23 kg/m2, almost half were centrally obese and 29% met the
criteria for metabolic syndrome. The individual relative-risk of CVD ranged from 0.62 to 15, and 13% had a
moderate-to-high 10-year CVD risk score. Regression models showed that lower physical HRQoL was predicted
by higher BMI and lower mental HRQoL. Higher Defined Daily Dose, clozapine, younger age and male gender
were found to explain 40% of the variance in CVD relative risk.
Conclusion: The findings indicate that cardiometabolic health risks in people with SSD may be more
common than those reported in the general Hong Kong population. The results also provide further support
for the need to consider antipsychotic polypharmacy and higher doses of antipsychotics as factors that may
contribute towards cardiometabolic risk in Chinese patients with SSD. Clinicians in Hong Kong should
consider using routine CVD risk screening, and be aware that younger male patients who are taking clozapine
and prescribed higher Defined Daily Dose seem to have the highest relative-risk of CVD.
Trial registration: Clinicaltrials.gov NCT02453217. Prospectively registered on 19th May 2015.
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Background
The poor cardiometabolic health state of people diagnosed
with schizophrenia–spectrum disorders (SSD) and other
severe mental illnesses (SMI) is a major clinical concern
and a priority area for health services improvement world-
wide [1–3]. It is now well recognised that compared with
the general population people with SMI have a higher risk
of developing obesity-related issues such as hypertension,
stroke, metabolic syndrome (MES), and type-2 diabetes
[4–8]. For example, it has been regularly reported that the
risk of obesity in people with SMI is at least two times
greater than in the general population [4].
In addition to obesity making a significant contribu-
tion towards the reduced life expectancy of people with
SMI [9, 10], it may also negatively impact on patients’
quality of life; studies conducted in the United States
and Canada have shown that lower levels of physical
health-related quality of life (HRQoL) in people with
SSD are related to higher Body Mass Index (BMI) and
waist circumference measurement [11–13]. Although
physical HRQoL has been shown by some studies to be
linked with obesity-related measures in SSD, a similar
connection between mental HRQoL and body weight is
not consistently reported in the literature [12, 14]. The
relationship between MES and reduced HRQoL in
people with SSD has also been investigated in Europe
and the United States, with some studies reporting a sig-
nificant association [15], whilst others identified no such
connection [16].
Cardiovascular diseases are also commonly seen, and
poorly treated in people with SSD. A meta-analysis in-
volving 13 studies demonstrated that schizophrenia is
associated with increased incidence of total cardiovascu-
lar disease (CVD), stroke, coronary heart disease (CHD)
and congestive heart failure, with pooled relative-risks
ranging from 1.2 to 1.81 [8]. The survival rates of SSD
patients with CHD are lower than the general popula-
tion with CHD; Harris and Barraclough [17] reported
90% more deaths and Lahti et al. [18] reported a 2.9
relative risk of mortality when compared to people with-
out a SMI who were diagnosed with CHD. Despite the
increased prevalence of CVD, some studies have also
shown that compared to the general population patients
with SMI are less likely than to receive surgical interven-
tions for CHD [19], have medications prescribed for
CVD [20], and/or receive CVD risk screening tests [21].
The concerns about the increased prevalence of CVD
in people with SSD have led to international calls for
regular routine screening for CVD in this patient group
[2, 22–25]. In line with these recommendations, a num-
ber of structured CVD risk assessment tools are now
used within health screening programmes for people
with SMI [1, 26]. The QRISK®2 [27, 28] and the Fra-
mingham coronary heart disease risk score [29] have
both been used to measure CVD risk scores in this pa-
tient group in a variety of clinical settings [1, 30]. Very
few such studies have been conducted in Asian coun-
tries; one example is Tay, Nurjono and Lee [31] who
used the Framingham risk score to determine the 10 year
CVD risk of patients with SSD in Singapore. The results
of this study demonstrated that the SSD participants had
a mean 10 year CVD risk of 4.6% compared to 3.1% in
the non-SSD comparison group. The QRISK®2 tool is
now increasingly used instead of the Framingham score
[30] because it incorporates additional risk factors (for
example, ethnicity, past history of smoking and family
history of CVD). One UK study using the QRISK®2
found that patients with SMI in high-security inpatient
forensic settings were more than twice-as-likely to have
a high risk of CVD compared to people in the commu-
nity without a SMI [28].
Numerous factors are likely to negatively influence the
cardiometabolic health of people with SSD; including
poor access to health services, unhealthy lifestyle behav-
iours, genetic predispositions and treatment-related is-
sues [4, 32, 33]. Although the potential iatrogenic effects
of treatment are only one factor that is likely to interact
with a range of other influences on physical health, pre-
vious studies have consistently reported that anti-
psychotic medication is associated with increased risk
for a range of cardiometabolic disorders [34, 35]. A large
systematic review [36] also convincingly demonstrates
that some antipsychotics are associated with at least
twice the risk of MES, when compared with un-
medicated people with SMI. Although individual anti-
psychotic medications are clearly associated (in varying
degrees) with weight gain and type 2 diabetes [37], the
relationships between the dosages, types and combined
use (polypharmacy) of antipsychotic drugs and cardio-
metabolic health problems is not so clear. There is con-
flicting evidence from some cohort studies that the
duration of exposure to antipsychotic medication, use of
antipsychotic polypharmacy and higher antipsychotic
dosages are linked to increased cardiovascular-related
mortality in people with SSD [38–40]. A recent study
conducted with Thai patients with SSD reported that
BMI was significantly greater in patients prescribed anti-
psychotic polypharmacy as opposed to those prescribed
monotherapy [41]. Nevertheless, it is still uncertain if a
direct relationship exists between antipsychotic polyphar-
macy and weight gain in all patients with SSD [42, 43];
whereas systematic reviews have highlighted that anti-
psychotic polypharmacy is most likely to be associated
with greater weight gain in younger people [5, 44].
There are very few studies conducted globally examin-
ing the potential relationships between cardiometabolic
health risks, HRQoL and doses/combined use of pre-
scribed antipsychotics. Therefore, the first objective of
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this study was to establish the level of CVD relative risk
(using QRISK®2) and prevalence of obesity (BMI and
waist circumference) in community-based Chinese
people prescribed antipsychotic medications for SSD.
The second objective was to examine potential relation-
ships between prescribed antipsychotic treatment/clin-




This observational, cross-sectional descriptive study re-
ports the results of the baseline measurements of a ran-
dom sample of patients (n = 82) participating in a
randomised controlled trial of physical health intervention
for Chinese people with severe mental illness. The on-
going trial was prospectively registered online at Clinical-
trials.gov (reference number NCT02453217). We report
the current study in accordance with the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [45]. The RCT was designed to test
the effectiveness and acceptability of the Chinese Health
Improvement Profile (CHIP) intervention compared to
treatment as usual on patients’ self-perceived physical
well- being over a 12-month period. The RCT was neces-
sary in order to robustly test the promising effects of the
CHIP intervention observed in our earlier prospective
case series study.
Study setting
The study was conducted in a Community Psychiatric
Service (CPS) in the New Territories, the largest geo-
graphical region of Hong Kong SAR, China. The multi-
disciplinary community psychiatric team provided both
crisis intervention and longer-term, recovery-focused
community psychiatric services for people with different
types of mental health problems.
Ethical issues
The study was approved by the Clinical Research Eth-
ics Committee of Hospital Authority, Hong Kong and
the Human Subjects Research Ethics Committee of
The Hong Kong Polytechnic University prior to the
start of the study. Patients were required to give writ-
ten informed consent to take part in the study and for
permission to access their medical records. The par-
ticipants’ information sheets clearly stated voluntary
participation and rights of withdrawal from the study
at any point without any negative treatment-related
consequences.
Recruitment and selection
Patients were recruited for the ongoing cluster random-
ized controlled trial (RCT). The participant inclusion
criteria for the RCT were patients aged 18–65 years with
an ICD10 diagnosis of a SMI (schizophrenia and other
related psychotic disorders, bipolar disorder, or major
depression). A total of 510 patients with SMI were
screened from the caseloads of 12 Community Mental
Health Nurses (CMHNs). Potential participants (n = 155)
were excluded if they were judged as being incapable of
providing informed consent, currently an inpatient, or if
they were diagnosed with co-morbidity of another
chronic medical/or mental disorders such as learning
disability, substance misuse disorders and organic brain
diseases. A list of 15 eligible patients from each of the
CMHNs caseloads was randomly generated using an ex-
ternal online randomization service (sealedenvelope.-
com); and they were approached until a minimum of
140 had agreed to take part. This minimum sample size
was calculated for the RCT (assuming a medium-large
effect size for the primary outcome measure, a signifi-
cance level of 0.05 and a potential attrition rate of 30%).
A total of 23 patients (14% of 165 approached) did not
agree to participate and one patient was recruited but
later found to be ineligible, resulting in 141 patients re-
cruited into the RCT. We did not record the demo-
graphic or clinical characteristics of those patients who
refused to participate, consequently we are unable to as-
certain if they differed significantly from patients who
agreed to take part.
For the current nested observational study, we analysed
data from outpatients with any types of SSD who were
aged 25–65 years and prescribed antipsychotic medica-
tion. We wanted to focus on patients with SSD in order to
directly compare the findings with other SSD studies, and
as the rates of CVD risk and obesity vary greatly in ac-
cordance with the type of SMI diagnosis we did not in-
clude data from patients with a diagnosis of bipolar
disorder, and/or major depression. It was also necessary to
exclude patients <25 years old in order to improve the
predictability of QRISK®2 scores (the minimum age that
can be entered into the QRISK®2 calculator is 25 and
therefore the algorithm would underestimate the relative
risk of patients aged <25 years). Subsequently, 59 patients
were excluded as ineligible due to age, diagnosis, or not
being prescribed antipsychotics; resulting in a final sample
of 82 participants.
Data collection procedures and measures
The 12 CMHNs undertook data collection as baseline
measurements for the cluster RCT either in the CPS
clinic or at patients’ homes. All recruitment and base-
line measurements were completed before the ran-
domisation of the CMHNs into the intervention or
treatment-as-usual group. Data were collected from
July to September 2015.
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Demographic and clinical information
The CHMNs recorded patients’ height, weight, BMI,
waist circumference measurement, heart rate (radial
pulse), and blood pressure. Blood pressure was recorded
using a digital sphygmomanometer whilst participants
were in a seating position, weight was measured using a
digital scale and a digital stadiometer was used to meas-
ure height. The CMHNs were instructed to record waist
circumference whilst patients were stood in a relaxed
position using a measuring tape placed snugly across the
midpoint between the lower rib and the top of the iliac
crest at a level parallel to the floor. In addition, all recent
(≤1 year) clinical data relating to the physical state of
participants (i.e. temperature, respiration rate, urine
tests, fasting blood glucose levels, lipid/cholesterol levels,
liver function tests and serum prolactin levels) that were
routinely recorded as part of standard practice in the
electronic patient records system were also examined
and recorded. Prevalence of obesity was calculated with
gender/ethnicity specific waist circumference measure-
ments and the BMI (kg/m2). Data relating to smoking
status, presence of rheumatoid arthritis, diabetes, heart
and kidney diseases, and family history of CVD were ob-
tained from the patients or their medical records.
Prescribed antipsychotic treatment
Types of antipsychotics, dosage and formulations cur-
rently prescribed to patients were recorded by the
CHMNs from the information in the medical records/
prescription charts. To facilitate the direct comparison
across patients on different antipsychotics and identify/
examine the relationship between the dosages and the
CVD risk/obesity, a standardized and reliable unit of
dosage measurement was necessary (i.e. the Defined
Daily Dose (DDD) [46]. The system of DDD is defined
as “the assumed average maintenance dose per day for a
drug used for its main indication in adults” and is rec-
ommended as an international standard for drug
utilization studies by the World Health Organization
[47]. A global average is assigned as the single DDD for
each drug and route of administration. For long-acting
injections, the DDDs are based on the average recom-
mended doses divided by the dosing interval. Prescribed
dosages of antipsychotics for patients was converted into
multiples of the Defined Daily Dose (DDD) for each in-
dividual antipsychotic by dividing the prescribed daily
dose by the DDD. For patients on more than one anti-
psychotic, the multiples of DDD for each drug were
summed up to give a cumulative dosage measurement.
Cardiovascular risk scores
The version 2 of QRISK® (QRISK®2-2015) [27, 28] was
used to calculate the 10-year CVD risk score of each
participant. The QRISK®2 score and an associated
individual CVD relative risk (relative to a person of the
same age, sex and ethnicity without clinical indicators of
risk and a cholesterol ratio of 4.0, systolic blood pressure
of 125 and an ethnicity-specific healthy BMI) were esti-
mated by entering a number of factors into the online
QRISK®2 -2015 calculation tool (https://qrisk.org/2015/).
These factors included: age, sex, ethnicity, height,
weight, smoking status, systolic blood pressure, choles-
terol/high-density lipoprotein (HDL) ratio, hypertension
treatment, presence of rheumatoid arthritis, diabetes,
heart and kidney diseases, and family history of CVD.
The test results recorded closest in time to the an-
thropometric measures were used to calculate cardiovas-
cular risk scores. Where test results were unavailable, or
more than 1-year-old, the values were left blank and
missing items were automatically imputed by the
QRISK®2 calculator with predicted values based on the
patient’s ethnicity, age and sex. The QRISK®2 algorithm
was developed from the QResearch medical database of
2 million patients collected at 550 general practices in
UK from 1993 to 2008 and is updated annually to reflect
the actual changes of the population. Compared to Fra-
mingham score, the equation of QRISK®2 was derived
from more recent and diverse ethnic groups (and the de-
rivative cohort consisted of almost 20,000 people of
Chinese ethnicity). It was also based on a larger variety
of data (having additional data on ethnicity, family med-
ical history, socio-economic status, and other clinical
factors). The predictability of QRISK®2 was validated in
samples of the QResearch database [27] and external
data sources [48, 49] and compared with the corre-
sponding Framingham scores. The results showed
QRISK®2 outperformed Framingham score in respect to
discrimination (QRISK®2 predicted 38% of the variation
in men and 43% in women compared with Framing-
ham’s 35 and 39% respectively). In 2010 the UK’s Na-
tional Institute for Health and Care Excellence
guidelines stated that the Framingham risk algorithm
should not be used for CVD risk assessment unless it
was considered together with other approaches (such as
QRISK®2) [50], and the UK’s Royal College of Psychia-
trists now suggest to use the QRISK®2 to estimate CVD
risk in people with SSD [1].
Prevalence of metabolic syndrome (MES)
The consensus criteria of metabolic syndrome (MES) for
Chinese populations from the International Diabetes Fed-
eration (IDF) [36] were used. Three out of five parameters,
including central obesity (waist circumference of ≥80 cm
for females and ≥90 cm for males) plus two additional ones
from the following four aspects, including: raised blood
pressure (systolic BP ≥130 or diastolic BP ≥85 mm/Hg), re-
duced HDL (<1.03 mmol/L in males, <1.29 mmol/L in
females), raised triglycerides (≥1.7 mmol/L) and elevated
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fasting plasma glucose (≥ 5.6 mmol/L), were used to define
the presence of MES in the participants.
Health-related quality of life
Patients self-reported their perceived HRQoL using
the widely used and well-established 12-Item Short
Form Survey 2nd version (SF12v2). Physical HRQoL
was calculated using the physical component subscale
(PCS) and mental HRQoL with the mental compo-
nent subscale (MCS). The SF12v2 was developed by
Ware, Kosinski, and Dewey [51] as a shorter version
of the previous SF36 [52]. The Hong Kong Chinese
version of the SF12v2 demonstrated good test–retest
reliability and internal consistency (intraclass correl-
ation 0.82; Cronbach’s alpha 0.67) for a Chinese adult
population [53].
Data analysis strategy
IBM® SPSS® software version 21 for Windows® was used
for all analyses. The clinical characteristics, prescribed
antipsychotic medication, prevalence of obesity and
metabolic diseases, cardiometabolic risk levels, and
HRQoL among the participants were summarised by
descriptive statistics. Relationships between these above
and the other health parameters were explored by cor-
relation and tests of between group differences. Para-
metric (i.e. independent sample T (two-tailed) or
ANOVA) and non-parametric (i.e. Mann-Whitney U or
Kruskal-Wallis) tests were used to examine the differ-
ences in BMI/waist circumference, QRISK®2 score/
CVD relative risk, and HRQoL scores across different
antipsychotic medication usage groups in terms of
their: number of types of antipsychotics (1-3), anti-
psychotic polypharmacy (yes/no,) antipsychotic combi-
nations (first generation, second generation, first and
second generation, long-acting intramuscular injection,
oral, and both oral and long acting intramuscular in-
jection), and Clozapine and DDD ranges. Multiple
step-wise linear regression analyses were performed to
identify which of the statistically significant treatment-
related and clinical/patient-related variables could satisfac-
torily explain the variance in physical HRQoL and CVD
relative risk. The level of significance was set at p < .05 for
all tests.
Results
Demographic and clinical characteristics
The demographic and clinical characteristics of partici-
pants are summarised in Table 1.
Data from a total of 82 participants with a mean age
of 49 years (SD = 8.57, range 30–65) were analysed.
Nearly 90% of the patients were diagnosed with schizo-
phrenia for more than 10 years and had an average of 4
hospital admissions. In spite of the relatively high
prevalence of metabolic syndrome (29%), very few were
receiving diabetes (8.5%) or cholesterol treatments
(3.7%). Around one-third were on antihypertensive
medication (n = 25), however only seven were diagnosed
with hypertension, with the majority (n = 18) being pre-
scribed propranolol for controlling anxiety or extrapyr-
amidal side effects. A total of 28 patients (34%) were
current smokers.
About one-third of the patients were prescribed more
than one type of antipsychotic (antipsychotic poly-
pharmacy). Most were on second-generation antipsy-
chotics (SGA); however, about 15% were on both
first-generation antipsychotics (FGA) and SGA. Over
one-third were prescribed long-acting intramuscular
injections (LAI), and around a quarter was taking
both LAIs and oral formulations. According to the
Defined Daily Dose (DDD) suggested by the World
Health Organisation, 61% of patients were prescribed
antipsychotics in excess of the recommended adult
DDD (>1.0 cumulative DDD).
Cardiometabolic health & health-related quality of life
The cardiometabolic health risks and HRQoL scores of
participants are presented in Table 1. Cardiometabolic
health risks were observed to be very common; over
two-thirds were found to have an unhealthy BMI (≥23
kgm2), nearly half were obese in terms of both BMI and
waist circumference, and 29% met the IDF criteria of
metabolic syndrome. In terms of QRISK®2 scores, certain
participants (13%) showed a moderate-to-high CVD risk
score (≥10%); whereas, the overall 10-year CVD individ-
ual relative risk was high with a mean of 2.8 (SD = 2.96)
and median of 1.8 (IQR = 1.87). Nevertheless, there was
a wide range of 10 year CVD relative risk (between 0.62
and 15) among the patients.
Relationships between demographic/clinical
characteristics, cardiometabolic health risks and HRQoL
The correlations between demographic/clinical charac-
teristics, cardiometabolic health and HRQoL are pre-
sented in Table 2. Factors significantly related to BMI
included a weak negative correlation with age (p = .045)
and weak positive correlation with number of previous
admissions (p = .015). Age was also negatively corre-
lated with CVD relative risk level (p < .001). Waist
circumference measurement was positively correlated
number of previous hospital admissions (p < .001).
The two SF12v2 subscale scores were correlated to
each other (p = .006) and increased BMI was nega-
tively correlated with PCS (p = .032). No other signifi-
cant correlations were found between demographic/
clinical characteristics, cardiometabolic health risks
and HRQoL.
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Table 1 Demographic, clinical and treatment characteristics of
study participants (N = 82)
Demographics
Male – N (%) 49 (59.8)
Female 33 (40.2)
Age in years – Mean (SD), range 48.67 (8.57), 30–65
Duration of illness in months – Mean (SD),
range
204.03 (138.12), 4–720
Numbers of previous psychiatric admissions
–Mean (SD), range
3.97 (4.17), 0–20










Employment Status – N (%)
Full time 19 (23.2)
Part time 5 (6.1)
Unemployed 40 (48.8)
Other 18 (22.0)
Psychiatric Diagnosis – N (%)
Schizophrenia 40 (48.8)





Smoking status – N (%)
Non smoker 50 (61.0)
Ex-smoker 1 (1.2)
Light smoker (<10 per day) 5 (6.1)
Moderate smoker (10–19 per day) 11 (13.4)
Heavy smoker (≥20 per day) 15 (18.3)
Medication Treatment – N (%)
Prescribed an antihypertensive 25 (30.5)
Prescribed a statin 3 (3.7)
Prescribed diabetes treatment 7 (8.5)
Prescribed antipsychotic polypharmacy 28 (34.1)




Prescribed psychotropic medications – N (%)
First Generation Antipsychotics 35 (42.7)
Table 1 Demographic, clinical and treatment characteristics of
study participants (N = 82) (Continued)








Clozapine and another antipsychotic 5 (6.1)
First and Second Generation Antipsychotics 12 (14.6)
Long acting intramuscular antipsychotic
injection
31 (37.8)





Sodium valproate 7 (8.5)
SSRI antidepressant 2 (2.4)
Prescribed Dosage of Antipsychotics
Cumulative multiples of DDD – Mean (SD),
range
1.62 (1.08), 0.1–5.14
≤1.0 DDD – N (%) 32 (39.0)
1.1–2.0 DDD – N (%) 26 (31.7)
>2.0 DDD – N (%) 24 (29.3)
Cardiometabolic Health
BMI (kg/m2) – Mean (SD) 24.81 (3.73)
BMI underweight – N (%) 3 (3.7)
BMI healthy – N (%) 22 (26.8)
BMI overweight – N (%) 18 (22.0)
BMI obese I – N (%) 33 (40.2)
BMI obese II – N (%) 5 (6.1)
Waist circumference obese (≥80 cm
females, ≥90 cm males) – N (%)
40 (48.8)
Metabolic syndrome (meets IDF criteria)
– N (%)
24 (29.3)
QRISK®2 10-year CVD risk score – Mean (SD) 5.28 (5.45)
<10% CVD risk score (low) – N (%) 71 (86.6)
10–19.9% CVD risk score (moderate) – N (%) 9 (11.0)
20% + CVD risk score (high) – N (%) 2 (2.4)
10-year CVD relative risk – Mean (SD) 2.80 (2.96)
– Median (IQR) 1.80 (1.87)
Health-Related Quality of Life
Physical component score (PCS) – Mean (SD) 46.01 (7.11)
Mental component score (MCS) – Mean (SD) 46.93 (9.59)
BMI body mass index, CVD cardiovascular disease, DDD daily defined dose,
IDF international diabetes federation, SD standard deviation, NOS not
otherwise specified
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Relationships between prescribed antipsychotics, HRQoL
and cardiometabolic health risks
The main correlations between prescribed antipsy-
chotics, cardiometabolic health and HRQoL are shown
in Table 2. Greater numbers of types of prescribed
antipsychotics were significantly positively correlated
with increased BMI (p = .003) and elevated 10-year
CVD relative-risk (p = .014). Cumulative DDD was
positively correlated with BMI (p = .021), CVD relative
risk (p = .001) and diastolic blood pressure (p = .027).
There were no other significant correlations identified
between prescribed antipsychotics, cardiometabolic
health risks and HRQoL.
Differences in HRQoL across demographic/clinical
characteristic groups and antipsychotic treatment
regimens
Females had a higher MCS scores than males (Z = -2.30,
p = .022) with mean ranks of 36.54 (male) and 48.86
(female), but a significant gender difference was not
observed in the PCS scores. No significant relation-
ships were identified between HRQoL and any other
demographic/clinical characteristic or antipsychotic
treatment groups.
Differences in cardiometabolic health across
demographic/clinical characteristic groups
Table 3 shows the differences in cardiometabolic
health and HRQoL across demographic and clinical
characteristic groups. The presence of MES was
only associated with higher number of previous ad-
missions (mean ranks = 44.37 vs 32.81, p = .027) but
not any other demographic factor and clinical char-
acteristic. Males had a greater CVD relative risk
than females (p < .001).
Differences in cardiometabolic health risks across
antipsychotic treatment groups
Table 3 provides details of the test results for differences
in cardiometabolic health between antipsychotic treat-
ment groups.
BMI and central obesity
Patients prescribed a combination of oral and LAIs had a
greater BMI than participants prescribed medications via
a singular route of administration (p = .008). Patients pre-
scribed a combination of both FGA and SGA also had a
higher BMI compared to those on a single class of anti-
psychotic medication (p = .009). Bonferroni-corrected
post-hoc tests of one-way ANOVA analysis revealed that
patients prescribed with three different antipsychotic
drugs had a significantly higher BMI than those prescribed
with only one type, with a mean difference of 5.25 kg/m2
(p = .010).
A significant result of the ANOVA test revealed that
patients prescribed with a dosage of >2.0 DDD had
significantly higher BMI than those with dosages of
1.1–2.0 DDD or ≤1.0 DDD in the Bonferroni post-
hoc test (p = .001 and p = .011 respectively). Higher
multiples of DDD (>2.0 DDD) was also significantly
associated with higher waist circumference compared
to lower dosage (1.1–2.0 DDD) with a mean differ-
ence of 9.73 cm (p−.007) in Bonferroni post-hoc test.
Blood pressure and pulse
Kruskal-Wallis test showed significant differences of
diastolic blood pressure across dosage groups, p = .021);
Mann-Whitney U-tests indicate that difference be-
tween >2.0 DDD and ≤1.0 DDD groups was signifi-
cant (Z = -2.61, p = .009, mean ranks of 35.02 vs
23.61). Patients prescribed clozapine had a higher dia-
stolic blood pressure than those prescribed other
Table 2 Demographic and clinical characteristics correlated with body mass index, waist circumference, relative risk of
cardiovascular disease, HRQoL summary subscales and diastolic blood pressure
BMI Waist circumference CVD relative risk PCS MCS Diastolic blood pressure
Age in years
(n = 80–82)
a-.220, .049* a-.112, .315 -.386, < .001*** -.183, .099 .123, .269 .116, .299
Number of previous psychiatric admissions
(n = 77–78)
.276, .015* .386, .001*** .165, .149 -.182, .111 -.136, .236 .209, .067
Number of antipsychotic types
(n = 81–82)
.330, .003** .171, .124 .270, .014* -.123, .270 -.138, .217 .180, .106
Dosage of antipsychotics (DDD)
(n = 81–82)
.257, .021* .214, .054 .361, .001** -.149, .182 -.092, .413 .244, .027*
PCS
(n = 81–82)
-.239, .032* -.118, .291 -.005, .967 - .299, .006** -.047, .678
MCS
(n = 81–82)
.093, .409 .118, .289 .030, .789 .299, .006** - .077, .492
BMI body mass index, CVD cardiovascular disease, DDD daily defined dose, MCS mental component score, PCS physical component score
Variables in the table are Spearman’s rho (rs) or
aPearson’s r (r), followed by p-value
* p < .05, ** p < .01, *** p < .001
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Table 3 Differences in cardiometabolic health risk indicators across gender and antipsychotic treatment groups
BMI (kg/m2) Waist circumference (cm) Diastolic blood pressure Pulse CVD relative risk
MDa [95% CI] T p MDa [95% CI] T p MRb Z p MRb Z p MRb Z p
Gender 1.21 [0.46, 2.88] 1.44 .154 3.25 [-1.84, 8.34] 1.27 .208 46.24 (male) −2.22 .027* 44.76 (male) −1.15 .130 49.32 (male) −3.62 < .001***
34.45 (female) 36.67 (female) 29.89 (female)
Clozapine prescribed
(yes Vs no)
0.85 [-1.41, 3.11] 0.75 .456 3.07 [-3.60, 9.74] 0.92 .363 41.52 (no) −0.02 .985 56.04 (yes) −2.52 .012* 55.71 (yes) −2.45 .014*
41.39 (yes) 38.51 (no) 8.57 (no)
Oral and LAI
(combination Vs single route)
2.58 [0.71, 4.46] 2.74 .008** 4.30 [-1.60, 10.20] 1.45 .151 50.82 (combine) −1.96 .050 42.46 (single) −0.67 .505 53.68 (combine) −2.54 .011*
38.69 (single) 38.32 (combined) 37.83 (single)
1st and 2nd generation
antipsychotics
(combination Vs single class)
3.01 [0.77, 5.25] 2.67 .009** 2.98 [-4.13, 10.9] 0.83 .407 49.54 (combine) −1.28 .202 42.20 (single) −0.65 .519 59.50 (combine) −2.83 .005**
40.12 (single) 37.42 (combine) 38.41 (single)




5.25 [0.73, 9.77] 4.93 .010* 5.43 [-9.13, 19.98] 0.47 1.000 49.44 (two) 3.83 .147 43.45 (one) 1.14 .564 37.19 (one) 6.71 .035*
(one vs three) (one, two, three) 38.50 (three) 38.23 (two) 47.52 (two)
38.19 (one) 34.75 (three) 63.50 (three)
Dosage of prescribed
antipsychotics
(>2 DDD, 1.1–2 DDD,
≤1 DDD)
3.94 [1.57, 6.30] 8.73 .001*** 9.73 [2.22, 17.24] 5.28 .007** 49.90 (>2) 7.77 .021* 42.66 (≤1) 0.13 .940 52.04 (>2) 9.41 .009**
(>2 vs 1.1–2) (>2 vs 1.1–2) 44.44 (1.1–2) 40.81 (>2) 42.90 (1.1–2)
2.79 [0.52, 5.06] 8.73 .011* 32.81 (≤1) 40.71 (1.1–2) 32.45 (≤1)
(>2 vs ≤1)
CI confidence interval, MD mean difference, MR mean rank, BMI body mass index, CVD cardiovascular disease, DDD daily defined dose, LAI long acting intramuscular injection
aIndependent sample T-test, bMann-Whitney U-test, c1-way ANOVA (Bonferroni-corrected post-hoc test), dKruskal-Wallis test











antipsychotics (p = .012). Mann-Whitney U-tests of in-
dividual types of antipsychotics revealed a higher
pulse rate for male patients than females (p = .027).
No other significant differences were found in blood
pressure and pulse across gender or antipsychotic
treatment groups.
CVD relative risk
Patients prescribed a combination of oral antipsychotics
and long acting intramuscular antipsychotic injections
had a greater CVD relative-risk than those patients
given antipsychotics via a singular route of adminis-
tration (p = .011). Similarly, patients prescribed a com-
bination of both FGA and SGA also had a higher
CVD relative risk than those prescribed monotherapy
(p = .005). Patients taking clozapine were found to
have a greater CVD relative risk than those who were
not prescribed clozapine (p = .014).
Kruskal-Wallis test of CVD relative risk across the
antipsychotic dosage groups showed the differences were
significant in patients prescribed with dosages over the
WHO recommended DDD (p = .009). Mann-Whitney U-
tests indicated that the risks of >2.0 DDD and ≤1.0 DDD
groups were significantly different (Z = -3.20, p = .001)
with mean ranks of 36.54 and 22.47 respectively. Signifi-
cant differences in CVD relative risk across number of
antipsychotic types were also found using Kruskal-Wallis
test (p = .035); Mann-Whitney U-test showed that the
CVD relative risk of one type of antipsychotic (mean
rank = 28.2) is significantly less from that of three
types (mean rank = 47.0, Z = -2.15, p = .032).
Regression analysis of physical HRQoL and CVD
relative-risk
Stepwise linear regression analysis was performed to as-
sess the associations of BMI and MCS with PCS subscale
(of HRQoL) scores. Collinearity test confirmed the inde-
pendency of BMI and MCS (tolerance = .992, VIF =
1.008) and assumption of independent errors of residuals
was met (Durbin-Watson value = 1.574). Standard re-
sidual plots showed that the data contained no outliers
and met the criteria of normality. The model (F (2,
78) = 5.03, p = .009) with R2 of .114 and adjusted R2
of .091 showed that both BMI and MCS were signifi-
cant predictors. Beta-coefficients and p-values are
shown in Table 4.
Another stepwise linear regression was conducted to
explore the significant predictors of CVD relative risk.
The relative risk was studied instead of QRISK®2 score
because it was age, sex and ethnicity controlled and this
could provide more accurate results. Given the ratio na-
ture of the CVD relative risk variable and non-normal
distribution, we used transformed log-normal scores in
the stepwise linear regression. Explanatory treatment
variables that were found to be significantly associated
with CVD relative risk (including multiples of DDD,
number of antipsychotic types, combinations of oral and
LAI, combinations of FGA and SGA, clozapine pre-
scription) and possible demographic variables (age
and gender) were entered into the model. Collinearity
tests indicated that the VIF of these seven variables
were all <5 and thus multi-collinearity was not a con-
cern. A significant model including age, gender, DDD
and clozapine were found to explain 39.9% of the
variance in CVD relative risk (adjusted R2 = .399, F (4,
77) = 14.45, p < .001). Table 4 summarizes the details
of beta-coefficients of each contributing variable. Analysis
of residuals confirmed the data contained no outliers and
assumption of independent errors (Durbin-Watson
value = 1.921), normality, homogeneity of variance and
linearity were all met.
Discussion
The first objective of this study was to establish the
prevalence of cardiometabolic risks in the study popula-
tion (schizophrenia spectrum disorders; SSD) as indi-
cated by levels of overweight/obesity, CVD relative risk
and presence of MES. Over two-thirds of participants
(68%) were found to have a BMI ≥23 kg/m2 and almost
half were centrally obese. Recent estimates have sug-
gested that 39% of the Hong Kong population has a
BMI ≥23 kg/m2 [54] and thus our results indicate
Table 4 Results from multiple regression models: A) Physical
health-related quality of life (HRQoL) regressed on body mass
index and mental HRQoL. B) Relative risk of cardiovascular disease
regressed on age, gender, clozapine medication and antipsychotic
dosage
b SE Beta p Adjusted R2
A) PCS regressed on:
BMI (kg/m2) −0.516 0.203 −0.272 .013
MCS 0.167 0.079 0.226 .038
Constant 50.918 6.025 < .001
.091
(p = .009)
B) CVD relative risk
regressed on:
Prescribed DDD 0.198 0.063 0.283 .002
On clozapine 0.523 0.175 0.263 .004
Age (years) −0.030 0.008 −0.346 < .001
Gender (male = 1) −0.364 0.138 −0.238 .010
Constant 1.751 0.515 .001
.399
(p < .001)
b unstandardized regression coefficient, Beta standardized regression
coefficient, SE standard error, BMI body mass index, CVD cardiovascular
disease, DDD daily defined dose, MCS mental component score, PCS physical
component score
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that the patients in the current study have a 174% in-
creased risk of being overweight/obese when com-
pared with the general population. An earlier study
conducted by Guo et al., in 10 sites across mainland
China [55] reported that 54% of 896 patients with
schizophrenia had a BMI ≥23 kg/m2; compared to the
43% observed in the general Chinese population [56]
this equates to an increased risk of 126%. Therefore,
it is possible that people with SSD in Hong Kong face
greater health inequalities compared to their mainland
Chinese counterparts. However, there are numerous
potential alternative reasons for these disparities in
the results, such as all participants in Guo et al.’s
study being prescribed only one type of antipsychotic,
and a younger mean age and shorter duration of ill-
ness than participants in our current study.
The prevalence of metabolic syndrome (MES) in the
current study is 29% as opposed to 17% of people in the
general Hong Kong population [57, 58], suggesting a po-
tential increased risk for MES of 170% for Chinese
people with SSD in Hong Kong. The rate in the current
study in randomly selected patients with schizophrenia
is lower than the 35% observed in an earlier Hong Kong
study of a convenience sample of people with SMI [59].
The differences between these rates of MES may relate
to selection bias in the earlier study [59], in which the
non-randomised (convenience) sample were invited to
participate by their clinicians on a sequential basis. The
variations in rates of MES, levels of obesity and CVD
risks across different populations of people with SSD are
now well-documented; for example, prevalence rates
range between 19% and 68% dependent on their country,
ethnicity, age, gender, prescribed medications, MES cri-
teria used and duration of illness [4, 60]. Despite these
differences, the rates of MES are consistently observed
to be elevated in people with SSD when compared with
the general population [60].
In the current study over 13% of patients were found
to have a moderate-to-high 10-year CVD risk score (as
indicated by >10% on the QRISK®2), which is consider-
ably higher than the 8% reported in the large UK deriv-
ation cohort of people without SMI but less than the
16% observed in a community-based UK people with
SMI [28]. Similarly, based on a QRISK®2 mean score of
5.28% in our study and the mean Framingham scores of
8.5% in American patients with schizophrenia [35] (in
spite of different calculation methods for the QRISK®2
and Framingham scores), our results suggest that people
with SSDs in Hong Kong have a reduced CVD risk com-
pared to the US patients. Perhaps these findings are not
surprising given that the CVD rates and life expectancies
of the general populations of Hong Kong, the UK and
the US vary considerably. Although there are great dif-
ferences in average life expectancies, it is consistently
reported that SSD patients have mortality rates 2–2.5
higher than the general population across international
settings, and this has led to calls from the World Health
Organisation (WHO) to improve the prevention, identi-
fication, assessment and treatment of physical health in
people with SSD across the globe [25].
The second objective was to examine potential rela-
tionships between prescribed treatment/clinical charac-
teristics, CVD relative risk and health related quality of
life (HRQoL). Patients’ self-perceived physical HRQoL
(PCS) and mental HRQoL (MCS) were both lower than
the reported population norms of 50.2 (PCS) and 50.1
(MCS) in Chinese adults in Hong Kong as measured by
the SF-12v2 [61]. Therefore, the HRQoL of participants
in this study suggests mild-moderate levels of perceived
physical and mental health concerns. In line with previ-
ous studies we found a relationship between increased
BMI and lower physical HRQoL [12, 62]. In fact, BMI
was the strongest predictor of physical HRQoL in the re-
gression model (beta coefficient of -.272, p = .013), pro-
viding further evidence that reductions in BMI may
result in improvements in physical HRQoL. However, no
direct relationship was observed between mental
HRQoL and BMI, which is consistent with results from
other studies in people with SMI [12, 14]. It is also inter-
esting to note that although mental HRQoL was not
found to directly relate to measures of body weight, the
regression model revealed that MCS was a significant
explanatory variable for the variance in physical HRQoL
subscale scores (beta coefficient of .226, p = .038). There-
fore, the findings highlight a potential significant rela-
tionship between perceived mental and physical health,
and indicate that weight reduction interventions in this
patient group could have the potential to not only en-
hance physical HRQoL, but also to indirectly improve
mental HRQoL of these patients.
Unlike some previous studies [15] which found that
reduced HRQoL was associated with metabolic syn-
drome (MES), we did not find any differences in HRQoL
between the patients who did and who did not meet the
criteria for MES. Nor did we find any differences in self-
reported HRQoL in patients with low/high CVD
relative-risk, or identify significant correlations between
HRQoL and CVD relative risk. This is an important
finding because it may indicate that despite having an el-
evated risk of CVD or MES, patients do not perceive
their physical HRQoL as being low, and thus they may
be less likely to actively seek treatment and/or be moti-
vated to make lifestyle changes to improve their physical
health state. This reinforces the need to actively promote
routine cardiometabolic health assessment for all pa-
tients with SSD and share concerns about identified
risks using effective psychoeducational interventions.
We also did not find any relationship between HRQoL
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and antipsychotic Defined Daily Dose (DDD); which is
corresponded with a recent European study of patients
with schizophrenia of a similar mean duration of illness
[13]. This also could suggest that patients who are re-
ceiving higher dosage(s) of antipsychotic do not subject-
ively recognise any negative impacts on their physical or
mental HRQoL, as such they may be less likely to com-
plain about being on higher doses and thus might re-
quire appropriate screening and support to recognise
potential problems. These observations, in conjunction
with evidence suggesting that people with severe mental
illness are less likely to receive CVD risk screening tests
and are undertreated for CVD [19–21] highlight that
mental health care providers need to be particularly vigi-
lant in monitoring the cardiometabolic health of people
with schizophrenia, and should proactively promote
treatment as appropriate.
A large proportion of patients were prescribed
antipsychotic polypharmacy (34%) and cumulative
doses of antipsychotics that are in excess of the
WHO DDD (61%). This is surprising given that with
the exception of clozapine augmentation [63–65]
there is a lack of convincing evidence that anti-
psychotic polypharmacy is any more effective than
monotherapy in improving psychotic symptoms.
This is also concerning because our results show
that antipsychotic polypharmacy and a higher DDD
was associated with increased CVD relative risk, a
greater BMI, higher waist circumference measure-
ment and elevated diastolic blood pressure. These
results support the findings from some earlier stud-
ies which reported that metabolic changes seen in
people with SSD are greater in those prescribed
polypharmacy [43] and are often antipsychotic dose-
dependent [66]. The 34% of patients prescribed anti-
psychotic polypharmacy in our study is similar to
the median percentage of 32% for Asian countries
reported in a large systematic review which pooled
data from 147 studies in four geographical regions
[67]. The same review also reports the median per-
centages of antipsychotic polypharmacy use in Eur-
ope (23%), the US (16%) and Oceania (16.4%).
Therefore, our study results seem to be consistent
with earlier studies suggesting that staff in Asian
settings may be more likely to prescribe anti-
psychotic polypharmacy than their counterparts in
other areas of the world. This may highlight a need to re-
view local clinical/prescribing guidelines, critically review
patients’ prescriptions more frequently or consider staff
training requirements. However, this is a cross-sectional
study and thus it is impossible to ascertain the appro-
priateness of the use of more than one antipsychotic
drug for participants; it is possible that some poly-
pharmacy prescriptions were made for justifiable
reasons, such as the cross-titration of antipsychotic
medications, the use of co-prescribed aripiprazole to
reduce weight-gain or the augmentation of clozapine
to improve symptom response [68].
The regression model in this study also revealed that
DDD, clozapine, age and male gender explained almost
40% of the variance in participants’ CVD relative risk.
Age was found to be the strongest predictor of CVD
relative risk in the regression model (coefficient of -.346,
p < .001), which could possibly be explained by previous
observations that BMI makes a direct contribution to-
wards CVD risk and that antipsychotic-induced weight
gain is most marked in younger people [5, 44]. These
findings also replicate results from some earlier studies,
which indicated that antipsychotics appeared to directly
contribute towards CVD risk [69, 70] and also that
higher doses/polypharmacy are associated with an in-
creased risk of cardiometabolic disorders [38]. In the
current study it is difficult to be certain which combina-
tions of antipsychotics present the highest cardiometa-
bolic risks because the duration of exposure to different
antipsychotic treatment regimens was not recorded.
However, the results certainly seem to highlight that psy-
chiatrists in Hong Kong should aim to proactively min-
imise the dosages and reduce the number of different
antipsychotics that are prescribed for people with SSD.
Study limitations
This study has a number of methodological limitations
which could negatively impact on the validity and gener-
alisability of the findings. Although the participants were
randomly selected from the CMHNs caseloads the nar-
row inclusion criteria used to select the subgroup of pa-
tients analysed in the current cross-sectional study may
have introduced some selection bias. The 10 year CVD
risk estimates should be treated with some caution; des-
pite the QRISK®2-2015 calculation tool having an option
for Chinese ethnicity, the measure was not validated for
Chinese people with SSD living in Hong Kong. We were
also unable to objectively verify that the CMHNs adhered
to the suggested approach towards waist circumference
measurement and missing (or outdated) blood test data
were automatically imputed based on age, sex and
ethnicity-specific predicted values. Other possible influ-
ences on the relationships between antipsychotics and
cardiometabolic health (such as levels of medication ad-
herence, duration of exposure to antipsychotic regimens
and lifestyle behaviours) are potential unmeasured con-
founding variables. In addition, the relatively small sample
size may have increased the risk of errors and the
cross-sectional design is unable to demonstrate causal
relationships. Future research should therefore adopt
a prospective cohort study design which aims to examine
the potential relationships between antipsychotic treatment,
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obesity, HRQoL and CVD risk in a larger sample of ran-
domly selected people with SSD.
Conclusions
The 10-year CVD relative-risk estimates and high preva-
lence of obesity/metabolic syndrome suggest that Hong
Kong Chinese people with SSD may experience worse
cardiometabolic health than the general population. A
lower physical HRQoL was associated with a higher
BMI, and increased mental HRQoL was found to be re-
lated to greater physical HRQoL. Consequently, inter-
ventions that reduce obesity in this patient group could
directly improve self-perceived physical health quality of
life and indirectly enhance mental health quality of life.
Clinicians in Hong Kong should consider using routine
CVD risk screening for all patients with SSD, implement
physical health promotion interventions as appropriate,
and be aware that younger male patients who are pre-
scribed higher doses of antipsychotics seem to have the
most elevated relative risk of CVD. The relationships
observed between cardiometabolic health and polyphar-
macy/higher doses provide further evidence that anti-
psychotic treatment regimens are modifiable factors that
can contribute towards cardiometabolic risk and hence
the subsequent patient mortality rates.
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